S1PR1 and myeloid sarcoma: Fingolimod-phosphate initially activates lymphocyte S1P1 via high-affinity receptor binding, yet subsequently induces S1P1 down regulation so as to prevent lymphocyte egress from lymphoid tissues, thereby reducing auto-aggressive lymphocyte infiltration into the CNS and further preventing demyelination in MS [73].